Literature DB >> 29764839

Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A.

Manuel Buscarlet1, Sylvie Provost2, Yassamin Feroz Zada2, Vincent Bourgoin1, Luigina Mollica1,3,4, Marie-Pierre Dubé2,4, Lambert Busque1,3,4.   

Abstract

We analyzed DNA from polymorphonuclear (PMN) cells, monocytes, B cells, and T cells of 107 individuals with clonal hematopoiesis of indeterminate potential (CHIP) to perform lineage restriction analysis of different gene mutations. Three lineage categories were defined: myeloid (PMN with or without monocytes), myelolympho-B (myeloid and B cells), and multipotent (myeloid, B and T cells). Six individuals with aberrant patterns were excluded from analysis. Ninety-four had a single mutation (56 in DNMT3A, 24 in TET2, 7 in other genes [JAK2, ASXL1, CBL or TP53]). Fourteen had multiple mutations. The lineage restriction patterns of single DNMT3A- or TET2-mutated individuals were different. The proportion of myeloid restricted mutations was higher for TET2 (54.2%, 13 of 24) than for DNMT3A (23.2%, 13 of 56) (P < .05). It was similar for myelolympho-B category but with a 1.5 fold greater proportion of myeloid cells for TET2 individuals (P < .05). Importantly, 0% (0 of 24) of the individuals with TET2 mutation in the multipotent category in contrast to 35.7% (20 of 56) for DNMT3A (P < .01). The clone size predicted multipotent pattern for DNMT3A suggesting a time delay for extensive lineage clonal dominance. These distinctive features may be important in deciphering the transformation mechanisms of these frequent mutations.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29764839     DOI: 10.1182/blood-2018-01-829937

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Authors:  Wenbin Xiao; Maheetha Bharadwaj; Max Levine; Noushin Farnhoud; Friederike Pastore; Bartlomiej M Getta; Anne Hultquist; Christopher Famulare; Juan S Medina; Minal A Patel; Qi Gao; Natasha Lewis; Janine Pichardo; Jeeyeon Baik; Brian Shaffer; Sergio Giralt; Raajit Rampal; Sean Devlin; Robert Cimera; Yanming Zhang; Maria E Arcila; Elli Papaemmanuil; Ross L Levine; Mikhail Roshal
Journal:  Blood Adv       Date:  2018-12-11

2.  High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential.

Authors:  Lambert Busque; Maxine Sun; Manuel Buscarlet; Sami Ayachi; Yassamin Feroz Zada; Sylvie Provost; Vincent Bourgoin; Luigina Mollica; Marlies Meisel; Reinhard Hinterleitner; Bana Jabri; Marie-Pierre Dubé; Jean-Claude Tardif
Journal:  Blood Adv       Date:  2020-06-09

Review 3.  Hand in hand: intrinsic and extrinsic drivers of aging and clonal hematopoiesis.

Authors:  Jennifer M SanMiguel; Kira Young; Jennifer J Trowbridge
Journal:  Exp Hematol       Date:  2020-09-28       Impact factor: 3.084

4.  Stem cell donors should not be screened for clonal hematopoiesis.

Authors:  Christopher J Gibson; R Coleman Lindsley
Journal:  Blood Adv       Date:  2020-02-25

Review 5.  A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.

Authors:  Anuradha Kirtonia; Gouri Pandya; Gautam Sethi; Amit Kumar Pandey; Bhudev C Das; Manoj Garg
Journal:  J Mol Med (Berl)       Date:  2020-07-03       Impact factor: 4.599

6.  Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation.

Authors:  Johannes Frasez Soerensen; Anni Aggerholm; Gitte Birk Kerndrup; Marcus Celik Hansen; Ina Kathrine Lykke Ewald; Marie Bill; Lene Hyldahl Ebbesen; Carina Agerbo Rosenberg; Peter Hokland; Maja Ludvigsen; Anne Stidsholt Roug
Journal:  Blood Adv       Date:  2020-03-10

7.  Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction.

Authors:  Ying Wang; Soichi Sano; Yoshimitsu Yura; Zhonghe Ke; Miho Sano; Kosei Oshima; Hayato Ogawa; Keita Horitani; Kyung-Duk Min; Emiri Miura-Yura; Anupreet Kour; Megan A Evans; Maria A Zuriaga; Karen K Hirschi; Jose J Fuster; Eric M Pietras; Kenneth Walsh
Journal:  JCI Insight       Date:  2020-03-26

Review 8.  The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation.

Authors:  Mariam T Nawas; Johannes Schetelig; Frederik Damm; Ross L Levine; Miguel-Angel Perales; Sergio A Giralt; Marcel R VanDenBrink; Maria E Arcila; Ahmet Zehir; Elli Papaemmanuil; Anja Klussmeier; Alexander H Schmidt; Stephanie Maiwald; Kelly L Bolton; Roni Tamari
Journal:  Blood Rev       Date:  2020-08-24       Impact factor: 8.250

Review 9.  Clonal Hematopoiesis and Its Impact on Cardiovascular Disease.

Authors:  Soichi Sano; Ying Wang; Kenneth Walsh
Journal:  Circ J       Date:  2018-09-04       Impact factor: 2.993

10.  Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.

Authors:  Jean Pegliasco; Pierre Hirsch; Christophe Marzac; Françoise Isnard; Jean-Côme Meniane; Caroline Deswarte; Philippe Pellet; Céline Lemaitre; Gwendoline Leroy; Graciela Rabadan Moraes; Hélène Guermouche; Barbara Schmaltz-Panneau; Florence Pasquier; Chrystelle Colas; Patrick R Benusiglio; Odile Bera; Jean-Henri Bourhis; Eolia Brissot; Olivier Caron; Samy Chraibi; Pascale Cony-Makhoul; Christine Delaunay-Darivon; Simona Lapusan; Flore Sicre de Fontbrune; Pascal Fuseau; Albert Najman; William Vainchenker; François Delhommeau; Jean-Baptiste Micol; Isabelle Plo; Christine Bellanné-Chantelot
Journal:  Leukemia       Date:  2021-06-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.